Cargando…

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals

Detalles Bibliográficos
Autores principales:	Pereira, A, Lopes da Cruz, JP, Carvalho, C, Gonçalves, C, Antunes, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112884/ http://dx.doi.org/10.1186/1758-2652-13-S4-P11

Ejemplares similares

First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting
por: Clumeck, Nathan, et al.
Publicado: (2014)

Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment
por: Shiau, Stephanie, et al.
Publicado: (2014)

The Frequency of Malaria Is Similar among Women Receiving either Lopinavir/Ritonavir or Nevirapine-based Antiretroviral Treatment
por: Skinner-Adams, Tina S., et al.
Publicado: (2012)

Impact of Efavirenz-, Ritonavir-Boosted Lopinavir-, and Nevirapine-Based Antiretroviral Regimens on the Pharmacokinetics of Lumefantrine and Safety of Artemether-Lumefantrine in Plasmodium falciparum-Negative HIV-Infected Malawian Adults Stabilized on Antiretroviral Therapy
por: Banda, Clifford G., et al.
Publicado: (2018)

An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir
por: Laker, Eva Agnes Odongpiny, et al.
Publicado: (2019)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

Comparing albuvirtide plus ritonavir-boosted lopinavir regimen to two nucleotide reverse transcriptase inhibitors plus ritonavir-boosted lopinavir in HIV-infected individuals who failed initial treatment: a retrospective comparative cohort study
por: Chen, Liyu, et al.
Publicado: (2022)

Virological outcomes in ARV-naïve patients switching or not from a first successful boosted PI-regimen to efavirenz, nevirapine or abacavir regimens
por: Bommenel, T, et al.
Publicado: (2010)

Nevirapine- Versus Lopinavir/Ritonavir-Based Initial Therapy for HIV-1 Infection among Women in Africa: A Randomized Trial
por: Lockman, Shahin, et al.
Publicado: (2012)

Early administration of ritonavir-boosted lopinavir could prevent severe COVID-19
por: Klement-Frutos, Elise, et al.
Publicado: (2021)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Nevirapine versus efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and tuberculosis infections in India: a pilot study
por: Sinha, Sanjeev, et al.
Publicado: (2013)

Pharmacokinetic interactions between artesunate-mefloquine and ritonavir-boosted lopinavir in healthy Thai adults
por: Rattanapunya, Siwalee, et al.
Publicado: (2015)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Kawalec, Paweł, et al.
Publicado: (2013)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study
por: Sinha, Sanjeev, et al.
Publicado: (2017)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Efficient immune reconstitution in HIV+ naïve patients (pts) starting a first lopinavir/ritonavir-containing regimen with low CD4 counts
por: Merlini, E, et al.
Publicado: (2010)

Propofol/lopinavir/ritonavir: Bradyarrythmia: case report
Publicado: (2020)

Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
por: Lan, Nguyen Thi Ngoc, et al.
Publicado: (2014)

The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
por: Kredo, T., et al.
Publicado: (2016)

Modulations of human placental transfer of lopinavir, ritonavir and enfuvirtide
por: Ceccaldi, Pierre-François, et al.
Publicado: (2010)

Population pharmacokinetics of lopinavir/ritonavir in Covid-19 patients
por: Alvarez, Jean Claude, et al.
Publicado: (2020)

Lopinavir/ritonavir: vomiting and watery diarrhoea: case report
Publicado: (2020)

Risk of bradycardia with lopinavir/ritonavir in COVID-19 patients
Publicado: (2020)

Remdesivir versus ritonavir/lopinavir in COVID-19 patients
por: Vitiello, Antonio, et al.
Publicado: (2020)

The administration of lopinavir/ritonavir via an enteral feeding tube()
por: Sirvent Segovia, Alejandro Esteban, et al.
Publicado: (2021)

Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis
por: Tigabu, Bereket Molla, et al.
Publicado: (2020)

Cardio-Metabolic Effects of HIV Protease Inhibitors (Lopinavir/Ritonavir)
por: Reyskens, Kathleen M. S. E., et al.
Publicado: (2013)

A Multicenter, Open Labeled, Randomized, Phase III Study Comparing Lopinavir/Ritonavir Plus Atazanavir to Lopinavir/Ritonavir Plus Zidovudine and Lamivudine in Naive HIV-1-Infected Patients: 48-Week Analysis of the LORAN Trial
por: Ulbricht, K.U, et al.
Publicado: (2011)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

Lopinavir/ritonavir in the treatment of HIV-1 infection: a review
por: Chandwani, Ashish, et al.
Publicado: (2008)

Hydroxychloroquine/lopinavir/ritonavir: Exanthema and eosinophilia: 12 case reports
Publicado: (2020)

Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
por: Mazan, Paula, et al.
Publicado: (2020)

Immunosuppressants/lopinavir/ritonavir interaction: Various toxicities: case report
Publicado: (2020)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

Dexamethasone/hydroxychloroquine/lopinavir/ritonavir: Various toxicities: case report
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_83qtcttsj739ji2lfh5es99vdn